Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
Owing to the absence of alphaGal epitopes in human cells and constant stimulation of the immune system by the symbiotic bacterial flora, humans develop high titers of natural antibodies against these epitopes. It has been demonstrated that syngeneic whole cell vaccines modified to express alphaGal epitopes could be used to generate a potent anticancer vaccine. In this study, we tested whether allogeneic whole cell cancer vaccines modified to express alphaGal epitopes would be effective for the treatment of murine melanoma. The alpha(1,3)galactosyltransferase (alphaGT) knockout mice (H-2) with preexisting subcutaneous and pulmonary tumors [alphaGal B16, H-2] received therapeutic vaccinations with S91M3alphaGal (H-2) whole cell allogeneic vaccines. These mice had better survival and reduced pulmonary metastasis burden compared with control mice treated with S91M3 vaccine cells. Vaccination with S91M3alphaGal-induced cytotoxic CD8 T cells recognizing the syngeneic alphaGal B16 tumors measured by adoptive transfer to recipients bearing pulmonary metastases. The presence of allo-antigens did not dominate the induction of immunity to "cryptic" tumor antigens and had helped in the generation of a more efficient vaccine to treat preexisting tumors when compared with classic autologous vaccines. Vaccination with allogeneic alphaGal vaccines did not induce signs of toxicity including changes in weight, hematology, chemistry, and histopathology of major perfused organs or autoimmunity in long-term murine models for breast, lung, and melanoma. This study established the safety and efficacy data of allogeneic alphaGal whole cell vaccines and constituted the basis for the initiation of human clinical trials to treat human malignancies.
Tumor Immunology Section, NewLink Genetics Corporation, ISU Research Park 2901 South Loop Drive, Ames, IA 50010, USA. grossi@linkp.com
Gabriela R
GR
Rossi
Mario R
MR
Mautino
Dana Z
DZ
Awwad
Katie
K
Husske
Henry
H
Lejukole
Marie
M
Koenigsfeld
William J
WJ
Ramsey
Nicholas
N
Vahanian
Charles J
CJ
Link
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000633:toxicity; D045744:Cell Line, Tumor; D005260:Female; D016219:Immunotherapy, Adoptive; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008546:Melanoma, Experimental / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy; D014312:Trisaccharides / Q000235:genetics*
D019496:Cancer Vaccines; D014312:Trisaccharides; C076569:alpha-galactosyl epitope